Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature
- Registry ID
- EUCTR2016-004091-21
- Source registry
- EUCTR
- Status
- GB - no longer in EU/EEA
- Phase
- PHASE2
- Sponsor
- University College London
- Start date
- 2017-08-18
- Last update
- 2026-08-16
Conditions
- Metastatic castrate resistant prostate cancer (prostate adenocarcinoma)
Summary
The trial is testing to see if metastatic prostate cancer patients who are no longer responding to their current treatment or previous treatment will respond to combination treatment of Nivolumab and Ipilimumub.
Locations
View on source registry